Strong Financial Performance: Royalty Pharma reported a 20% growth in Portfolio Receipts to $727 million and an 11% increase in Royalty Receipts to $672 million in Q2 2025. The company confidently raised its full-year Portfolio Receipts guidance to $3.05 billion to $3.15 billion, reflecting an anticipated growth of 9% to 12%.

Buyback and Capital Allocation: The company has repurchased 8 million shares in Q2 2025, totaling $1 billion in buybacks for the year. It allocated nearly $600 million towards new royalty transactions, demonstrating a commitment to returning capital to shareholders while pursuing growth opportunities.

Partnership with Revolution Medicines: Royalty Pharma announced a groundbreaking $2 billion funding partnership with Revolution Medicines for their Phase III oncology therapy, daraxonrasib. This innovative structure allows for funding tied to clinical milestones and is seen as a potential blueprint for future transactions, enhancing Royalty Pharma¡¯s position in the biotechnology space.